Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-25T17:18:52.431Z Has data issue: false hasContentIssue false
  • English
  • Français

Second-generation antipsychotics: a therapeutic downturn?

A commentary on: ‘Second-generation antipsychotics for schizophrenia: can we resolve the conflict?’ by Leucht et al. (2009)

Published online by Cambridge University Press:  10 September 2009

Shôn Lewis
Shôn Lewis*
Affiliation:
Professor of Adult Psychiatry, University of Manchester, UK
*
*Address for correspondence: Dr Shôn Lewis, Professor of Adult Psychiatry, University of Manchester, Manchester, UK. (Email: shon.lewis@manchester.ac.uk)
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Antipsychotic drugsclinical trialsmeta-analysisschizophrenia
Type
Commentary
Information
Psychological Medicine , Volume 39 , Issue 10 , October 2009 , pp. 1603 - 1606
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Davies, LM, Lewis, SW, Jones, PB, Barnes, TRE, Gaughran, F, Hayhurst, K, Markwick, A, Lloyd, H, on behalf of the CUtLASS team (2007). Cost effectiveness of first generation versus second generation antipsychotic drugs to treat psychosis: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry 191, 14–22.CrossRefGoogle Scholar
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321, 1371–1376.CrossRefGoogle ScholarPubMed
Jones, PB, Barnes, TRE, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, Murray, RM, Markwick, A, Lewis, SW (2006). Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia – cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 63, 1079–1086.CrossRefGoogle Scholar
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IPM, Gheorghe, MD, Rybakowski, JK, Galderisi, S, Libiger, J, Hummer, M, Dollfus, S, Lopez-Ibor, JJ, Hranov, LG, Gaebel, W, Peuskens, J, Lindefors, N, Riecher-Rossler, A, Grobbee, DE (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085–1097.CrossRefGoogle ScholarPubMed
Kane, JM, Honigfeld, G, Singer, J, Meltzer, H, and the Clozaril Collaborative Study Group (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789–796.CrossRefGoogle ScholarPubMed
Leucht, S, Kissling, W, Davis, JM (2009). Second-generation antipsychotics for schizophrenia: can we resolve the conflict?' Psychological Medicine. Published online: 1 April 2009. doi:10.1017/S0033291709005455.CrossRefGoogle ScholarPubMed
Lewis, SW, Barnes, TR, Davies, L, Murray, RM, Dunn, G, Hayhurst, KP, Markwick, A, Lloyd, H, Jones, PB (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32, 715–723.CrossRefGoogle ScholarPubMed
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RSE, Davis, SM, Davis, CE, Lebowitz, BD, Severe, J, Hsiao, JK (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.CrossRefGoogle ScholarPubMed
McEvoy, JP, Lieberman, JA, Stroup, TS, Davis, SM, Meltzer, HY, Rosenheck, RA, Swartz, MS, Perkins, DO, Keefe, RSE, Davis, CE, Severe, J, Hsiao, JK (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163, 600–610.CrossRefGoogle Scholar
Rosenheck, R, Perlick, D, Bingham, S, Liu-Mares, W, Collins, J, Warren, S, Leslie, D, Allan, E, Campbell, EC, Caroff, S, Corwin, J, Davis, L, Douyon, R, Dunn, L, Evans, D, Frecska, E, Grabowski, J, Graeber, D, Herz, L, Kwon, K, Lawson, W, Mena, F, Sheikh, J, Smelson, D, Smith-Gamble, V (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia – a randomized controlled trial. Journal of the American Medical Association 290, 2693–2702.CrossRefGoogle ScholarPubMed
Rosenheck, RA, Leslie, D, Sindelar, J, Miller, EA, Lin, H, Stroup, S, McEvoy, J, Davis, S, Keefe, RSE, Swartz, M, Perkins, D, Hsiao, J, Lieberman, JA (2006). Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 163, 2080–2089.CrossRefGoogle Scholar